- Original article
- Open Access
Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients
The Egyptian Journal of Internal Medicine volume 26, pages 6–14 (2014)
Hepcidin is a peptide hormone produced by the liver and appears to be the master regulator of iron homeostasis. This peptide is upregulated in inflammatory conditions, including uremia. Hepcidin functions to regulate (inhibit) iron transport across the gut mucosa, thereby preventing excess iron absorption and maintaining normal iron levels within the body. In this study, we aimed to investigate hepcidin levels and their relationship with the parameters of iron status, inflammation, anemia therapy, and parameters of dialysis efficiency in hemodialysis patients.
Patients and methods
Plasma hepcidin-25, inflammatory markers (high-sensitivity C-reactive protein and interleukin 6), and peripheral iron indices (serum iron, total iron-binding capacity, transferrin saturation and serum ferritin) were measured before hemodialysis in 40 end-stage renal disease (ESRD) patients treated with regular hemodialysis in a single dialysis unit as well as in 20 healthy individuals matched for age and sex serving as the control group.
Plasma levels of hepcidin-25 were significantly higher in hemodialysis patients compared with controls. In a simple correlation analysis, plasma hepcidin levels were positively correlated with ferritin, transferrin saturation, CRP, and interleukin 6; however, it was negatively correlated with hemoglobin, dose of epoitin-α, and dose of iron.
Serum hepcidin levels were associated with iron status and inflammation in maintenance hemodialysis patients, and the high hepcidin serum levels, found in hemodialysis (HD) patients, are dependent on the magnitude of the inflammatory process and on recombinant human erythropoietin doses. Hepcidin and its regulatory pathways are potential therapeutic targets, which could lead to effective treatment of anemia in chronic hemodialysis.
Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009; 22: 70–77.
KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11–S145.
Weiss G, Theurl I, Eder S, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883–890.
Verga Falzacappa MV, Muckenthaler MU. Hepcidin: iron hormone and anti-microbial peptide. Gene 2005; 364: 37–44.
Park CH, Valore EU, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806–7810.
Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anaemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037–1044.
Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323–342.
Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anaemia of CKD. Am J Kidney Dis 2010; 55: 726–741.
Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090–2093.
Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006; 507: 29–35.
Cui YJ, Wu QY, Zhou YQ. Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int 2009; 76: 1137–1141.
Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205–1213.
Rodkey FL. Binding of bromocresol green by human serum albumin. Arch Biochem Biophys 1964; 108: 510–513.
Kessler G, Wolfman M. An automated procedure for the simultaneous determination of calcium and phosphorus. Clin Chem 1965; 45: 290–296.
Goodwin JF. Quantification of serum inorganic phosphorus, phosphatase, and urinary phosphate without preliminary treatment. Clin Chem 1970; 16: 776–780.
Wahlefeld AW. Triglyceride determination after enzymatic hydrolys. In: HU Berger, editor. Methods of enzymatic analysis. 2nd English ed. (translated from 3rd German ed.). NY and London: Verlag Chemie Weinheim and Academic Press Inc.; 1974. 4: 1813–1835.
Flegg HM. An investigation for the determination of serum cholesterol by an enzymatic method. Ann Clin Biochem 1973; 10: 79–84.
Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972; 18: 499–502.
Trinder L. Determination of blood glucose using an oxidase–peroxidase system with a non-carcinogenic chromagen. Ann Clin Biochem 1969; 22: 158–161
Xu Y, Ding XQ, Zou JZ, et al. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res 2011; 39: 19611967.
Tessitore N, Girelli D, Campostrini N, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25: 3996–4002.
Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461–2463.
Kato A, Tsuji T, Luo J, et al. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115–121.
Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip system. Blood 2006; 108: 1381–1387.
Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976–981.
Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, et al.; Hepcidin expression in the liver : relatively low level in patients with chronic hepatitis C. Mol Med. 2007 Jan-Feb; 13: 97–104.
Kumar S, Raftery M, Yaqoob M, et al. Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. Perit Dial Int 2007; 27: 283287.
Liu XB, Nguyen NB, Marquess KD, et al. Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophage. Blood Cells Mol Dis 2005; 35: 47–56.
Kearney SL, E Nemeth, EJ Neufeld, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007; 48: 57–63.
Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia — the good, the bad, and the ugly. Kidney Int 2005; 67: 1216–1233.
Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204–3209.
Costa E, Pereira BJG, Rocha-Pereira P, et al. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol 2008; 28: 677–683.
Zaritsky J, Young B, Wang HJ, et al. Hepcidin: a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051–1056.
Van der Weerd NC, Grooteman MPC, Bots ML, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012; 7: e39783.
Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5: 1681–1689.
Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica 2008; 93: 90–97.
Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010; 115: 3616–3624.
Noxxon Pharma AG. 2011. Pipeline. NOX-H94, 44-nucleotide l-RNA oligonucleotide linked to 40 kDa PEG. Available at: http://www.noxxon.com/index.php?option_com_content&view_article&id_88&Itemid_100. [Accessed 29 May 2011]
Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 2012; 59: 444–451.
Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 2008; 111: 5727–5733.
Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096–1101.
Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181–186.
Zaritsky J, Young B, Gales B, et al. Reduction of serum hepcidin by haemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010; 5: 1010–1014.
Swinkels DW, Wetzels JFM. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 2008; 23: 2450–2453.
About this article
Cite this article
Ibrahim, I.A., Mohamad, U.M., Darweesh, H.A. et al. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients. Egypt J Intern Med 26, 6–14 (2014). https://doi.org/10.4103/1110-7782.132882
- iron status